Onconetix (ONCO) Cash from Financing Activities (2021 - 2026)
Onconetix (ONCO) posted quarterly Cash from Financing Activities of $631788.0 for Q1 2026, down 77.99% year-over-year from $2.9 million in Q1 2025, and down 90.35% quarter-over-quarter from $6.5 million in Q4 2025.
Onconetix (ONCO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Cash from Financing Activities for 6 consecutive years, with $631788.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 77.99% year-over-year to $631788.0; the TTM figure through Mar 2026 stood at $12.2 million (up 177.08% YoY), while the FY2025 annual figure was $14.5 million, up 114.33% from the prior year.
- Cash from Financing Activities declined to $631788.0 in Q1 2026 per ONCO's latest filing, from $6.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $17.6 million in Q1 2022 and bottomed at -$582838.0 in Q4 2022.
- Historically, Cash from Financing Activities has averaged $3.5 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 324.77% — and 2024, when it soared 10732.62%.
- Onconetix's Cash from Financing Activities stood at -$582838.0 in 2022, then jumped by 322.82% to $1.3 million in 2023, then grew by 0.32% to $1.3 million in 2024, then jumped by 402.51% to $6.5 million in 2025, then sank by 90.35% to $631788.0 in 2026.
- Business Quant data shows ONCO's Cash from Financing Activities at $631788.0 in Q1 2026, $6.5 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 4.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.17 Mn |
| Jun 30, 2026 | 4.17 Mn |
| Mar 31, 2026 | 631,788.00 |
| Mar 31, 2026 | 631,788.00 |
| Dec 31, 2025 | 6.55 Mn |
| Dec 31, 2025 | 6.55 Mn |
| Sep 30, 2025 | 4.29 Mn |
| Sep 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 744,574.00 |
| Jun 30, 2025 | 744,574.00 |
| Mar 31, 2025 | 2.87 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 578,643.00 |
| Sep 30, 2024 | 578,643.00 |
| Jun 30, 2024 | -343,426.00 |
| Jun 30, 2024 | -343,426.00 |
| Mar 31, 2024 | 5.21 Mn |
| Mar 31, 2024 | 5.21 Mn |